• 1. VSTA, 21 USC §151–159 (2020).

  • 2. Federal Food, Drug, and Cosmetic Act, 21 USC §301–399 (2020).

  • 3. Animal Drug Availability Act of 1996, Pub L No. 104–250, 110 Stat 3151.

  • 4. USDA. Guidelines for autogenous biologics. Veterinary Services Memorandum 800.69. Riverdale, Md: USDA APHIS Veterinary Services, 2002.

    • Search Google Scholar
    • Export Citation
  • 5. USDA APHIS. Viruses, serums, toxins, and analogous products; exemptions from preparation pursuant to an unsuspended and unrevoked license. Fed Regist 2015;80:2681926822.

    • Search Google Scholar
    • Export Citation
  • 6. USDA. Licensing guidelines for production platform technology-based, non-replicating, nonviable vaccines. Veterinary Services Memorandum 800.213. Riverdale, Md: USDA APHIS Veterinary Services, 2018.

    • Search Google Scholar
    • Export Citation
  • 7. USDA. Prescription platform product biologics. Veterinary Services Memorandum 800.214. Riverdale, Md: USDA APHIS Veterinary Services, 2018.

    • Search Google Scholar
    • Export Citation
  • 8. USDA APHIS. Viruses, serums, toxins, and analogous products; packaging and labeling. Fed Regist 2016;81:5942759436.

  • 9. USDA APHIS. Viruses, serums, toxins, and analogous products; single label claim for veterinary biological products. Fed Regist 2015;80:3966939675.

    • Search Google Scholar
    • Export Citation
  • 10. USDA APHIS. Product summaries page. Available at: aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries/product-summaries. Accessed Jun 17, 2020.

    • Search Google Scholar
    • Export Citation
  • 11. National Environmental Policy Act of 1969, 42 USC §4321 (2020).

  • 12. USDA APHIS. National Environmental Policy Act implementing procedures. Fed Regist 2018;83:2400324011.

  • 13. USDA APHIS. VSTA records and reports specific to international standards for pharmacovigilance. Fed Regist 2018;83:22832.

  • 14. APHIS. Adverse event reporting page. Available at: aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics/adverse-event-reporting/ct_vb_adverse_event. Accessed Jun 17, 2020.

    • Search Google Scholar
    • Export Citation

Advertisement

Review of updated regulations and product license categories for veterinary vaccines in the United States

Matthew M. Erdman DVM, PhD1, Nancy E. Clough DVM, PhD1, and Paul J. Hauer DVM, PhD1
View More View Less
  • 1 Center for Veterinary Biologics, Veterinary Services, Animal and Plant Health Inspection Service, USDA, Ames, IA 50010

Abstract

The USDA continues to consider and implement regulatory pathways for evolving scenarios, needs, and technologies. The intent of this report is to make veterinarians and other users of veterinary biologics aware of recent regulatory additions and changes, particularly in the area of veterinary vaccines. These include new licensure pathways to increase product availability, standardization of labeling, and increased transparency regarding adverse event reports and the efficacy and safety studies accepted by the USDA for product licensure. This report did not undergo scientific peer review.

Contributor Notes

Address correspondence to Dr. Erdman (matthew.m.erdman@usda.gov).